High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in Northern Tanzania and the emergence of dhps resistance mutation at codon 581

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Gesase, Samwel ^a   Gosling, Roly D ^b   Hashim, Ramadham ^a   Ord, Rosalynn ^b   Naldoo, Inbarani ^b,c   Madebe, Rashid ^a   Mosha, Jacklin F ^d   Joho, Angel ^a,d   Mandia, Victor ^a   Mrema, Hedwiga ^a   Mapunda, Ephraim ^a   Savael, Zacharia ^a   Lemnge, Martha ^a   Mosha, Frank W ^d   Greenwood, Brian ^b   Roper, Cally ^b   Chandramohan, Daniel ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DEOXYHYPUSINE SYNTHASE; DIHYDROFOLATE REDUCTASE; FANSIDAR; MOLECULAR MARKER; QUININE;

ARTICLE; CHILD; CLINICAL TRIAL; CODON; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; HAPLOTYPE; HUMAN; IN VIVO STUDY; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; OPEN STUDY; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROTOZOAL GENETICS; REINFECTION; TANZANIA; TREATMENT DURATION;

PLASMODIUM FALCIPARUM;

EID: 84887212543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004569     Document Type: Article

References (46)

1. Peters PJ, Thigpen MC, Parise ME, Newman RD (2007) Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Saf 30: 481-501.
2. Grobusch MP, Egan A, Gosling RD, Newman RD (2007) Intermittent preventive therapy for malaria: progress and future directions. Curr Opin Infect Dis 20: 613-620.
3. Jelinek T, Ronn AM, Lemnge MM, Curtis J, Mhina J, et al. (1998) Polymorphisms in the dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS) genes of Plasmodium falciparum and in vivo resistance to sulphadoxine/pyrimethamine in isolates from Tanzania. Trop Med Int Health 3: 605-609.
4. (2000) National Guidelines for Malaria Diagnosis and Treatment Ministry of health, United Republic of Tanzania.
5. Ronn AM, Msangeni HA, Mhina J, Wernsdorfer WH, Bygbjerg IC (1996) High level of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine in children in Tanzania. Trans R Soc Trop Med Hyg 90: 179-181.
6. Trigg JK, Mbwana H, Chambo O, Hills E, Watkins W, et al. (1997) Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Trop 63: 185-189.
7. Warsame M, Kilimali VA, Wernsdorfer WH, Lebbad M, Rutta AS, et al. (1999) Resistance to chloroquine and sulfadoxine-pyrimethamine in Plasmodium falciparum in Muheza district, Tanzania. Trans R Soc Trop Med Hyg 93: 312-313.
8. Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, et al. (2004) Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg 71: 696-702.
9. Vestergaard L, Riingwald P (2007) Respondinng to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. American Journal of Tropical Medicine and Hygiene 77: 153-159.
10. White NJ (2005) Intermittent presumptive treatment for malaria. PLoS Med 2: e3.
11. Chandler CI, Drakeley CJ, Reyburn H, Carneiro I (2006) The effect of altitude on parasite density case definitions for malaria in northeastern Tanzania. Trop Med Int Health 11: 1178-1184.
12. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ (1988) Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 85: 9109-9113.
13. Peterson DS, Walliker D, Wellems TE (1988) Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 85: 9114-9118.
14. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, et al. (1994) Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224: 397-405.
15. Triglia T, Cowman AF (1994) Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc Natl Acad Sci U S A 91: 7149-7153.
16. Omar SA, Adagu IS, Warhurst DC (2001) Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95: 315-319.
17. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, et al. (2002) Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
18. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, et al. (2004) Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health 9: 624-629.
19. Wilairatana P, Kyle DE, Looareesuwan S, Chinwongprom K, Amradee S, et al. (1997) Poor efficacy of antimalarial biguanide-dapsone combinations in the treatment of acute, uncomplicated, falciparum malaria in Thailand. Ann Trop Med Parasitol 91: 125-132.
20. Krudsood S, Imwong M, Wilairatana P, Pukrittayakamee S, Nonprasert A, et al. (2005) Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Trans R Soc Trop Med Hyg 99: 142-149.
21. Hyde JE (2008) Antifolate resistance in Africa and the 164-dollar question. Trans R Soc Trop Med Hyg 102: 301-303.
22. Hamel MJ, Poe A, Bloland P, McCollum A, Zhou Z, et al. (2008) Dihydrofolate reductase I164L mutations in Plasmodium falciparum isolates: clinical outcome of 14 Kenyan adults infected with parasites harbouring the I164L mutation. Trans R Soc Trop Med Hyg 102: 338-345.
23. McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, et al. (2006) Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis 194: 189-197.
24. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, et al. (2008) Emergence of a dhfr Mutation Conferring High-Level Drug Resistance in Plasmodium falciparum Populations from Southwest Uganda. J Infect Dis 197: 1598-1604.
25. Maxwell CA, Chambo W, Mwaimu M, Magogo F, Carneiro IA, et al. (2003) Variation of malaria transmission and morbidity with altitude in Tanzania and with introduction of alphacypermethrin treated nets. Malar J 2: 28.
26. GlaxoSmithKline (2008) Update on GSK's malaria treatments: Dacart and Lapdap. http://www.gsk.com/media/pressreleases/2008/ 2008_pressrelease_0014.htm.
27. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C (2003) Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 47: 1347-1354.
28. Snounou G, Zhu X, Siripoon N, Jarra W, Thaithong S, et al. (1999) Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Trans R Soc Trop Med Hyg 93: 369-374.
29. Anderson TJ, Su XZ, Bockarie M, Lagog M, Day KP (1999) Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology 119(Pt 2): 113-125.
30. Stepniewska K, White NJ (2006) Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J 5: 127.
31. Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, et al. (1997) Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol 89: 161-177.
32. Mbugi EV, Mutayoba BM, Malisa AL, Balthazary ST, Nyambo TB, et al. (2006) Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J 5: 94.
33. Schonfeld M, Barreto Miranda I, Schunk M, Maduhu I, Maboko L, et al. (2007) Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J 6: 2.
34. Mutabingwa T, Nzila A, Mberu E, Nduati E, Winstanley P, et al. (2001) Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 358: 1218-1223.
35. Gebru-Woldearegai T, Hailu A, Grobusch MP, Kun JF (2005) Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia. Am J Trop Med Hyg 73: 1131-1134.
36. Mockenhaupt FP, Ehrhardt S, Dzisi SY, Teun Bousema J, Wassilew N, et al. (2005) A randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria. Trop Med Int Health 10: 512-520.
37. Alker AP, Mwapasa V, Purfield A, Rogerson SJ, Molyneux ME, et al. (2005) Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi. Antimicrob Agents Chemother 49: 3919-3921.
38. A-Elbasit I, Alifrangis M, Khalil IF, Bygbjerg IC, Masuadi EM, et al. (2007) The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations inmodification of Plasmodium falciparum characteristics. Malar J 6: 108.
39. Jelinek T, Kilian AH, Kabagambe G, von Sonnenburg F (1999) Plasmodium falciparum resistance to sulfadoxine/pyrimethamine in Uganda: correlation with polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes. Am J Trop Med Hyg 61: 463-466.
40. Jelinek T, Kilian AH, Westermeier A, Proll S, Kabagambe G, et al. (1999) Population structure of recrudescent Plasmodium falciparum isolates from western Uganda. Trop Med Int Health 4: 476-480.
41. ter Kuile FO, van Eijk AM, Filler SJ (2007) Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 297: 2603-2616.
42. Tagbor HK, Chandramohan D, Greenwood B (2007) The safety of amodiaquine use in pregnant women. Expert Opin Drug Saf 6: 631-635.
43. Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG (2008) Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother 52: 1799-1805.
44. Djimdé AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, et al. (2003) Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558-563.
45. Njama-Meya D, Kamya MR, Dorsey G (2004) Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 9: 862-868.
46. McCollum AM, Mueller K, Villegas L, Udhayakumar V, Escalante AA (2007) Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America. Antimicrob Agents Chemother 51: 2085-2091.